Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04102098 · ClinicalTrials.gov registry record · Phase 3

A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

A Phase 3 study of Carcinoma, Hepatocellular, sponsored by Hoffmann-La Roche.

Active
Registry status
Phase 3
Development phase
668
Enrollment target
20
Study locations

NCT04102098 is a Phase 3 study of Carcinoma, Hepatocellular that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 668 participants, above the 588-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (14% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04102098, a Phase 3 study of Carcinoma, Hepatocellular, is active but no longer recruiting, sponsored by Hoffmann-La Roche.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
668 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for disease recurrence.

Conditions Studied

Carcinoma, Hepatocellular

Interventions

  • DRUG Bevacizumab
  • DRUG Atezolizumab

Study Locations (20)

Other

  • Lkh-Univ. Klinikum Graz - Graz
  • Klinikum Klagenfurt am Wörtersee - Klagenfurt
  • Medizinische Universität Wien - Vienna
  • Imeldaziekenhuis - Bonheiden
  • AZ Delta (Campus Rumbeke) - Roeselare

Texas

  • The University of Texas Southwestern Medical Center at Dallas - Dallas
  • MD Anderson Cancer Center - Houston

California

  • Kaiser Permanente Los Angeles - Los Angeles

Maryland

  • Mercy Medical Center - Baltimore

Michigan

  • Henry Ford Health System - Detroit

New York

  • Columbia University Medical Center - New York

Pennsylvania

  • Thomas Jefferson University - Philadelphia

Washington

  • Swedish Cancer Inst. - Seattle

Trial Details

FieldValue
Enrollment Target 668 participants
Start Date 2019-12-31
Est. Completion 2026-05-15
Phase Phase 3

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04102098

The ClinicalTrials.gov registry entry for NCT04102098 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 668 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 588-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (14% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Hepatocellular appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.

NCT04102098 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, Texas, California.

Frequently Asked Questions

What is clinical trial NCT04102098 about?

NCT04102098 is a clinical study titled "A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation". This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for disease recurrence.

What is the current status of trial NCT04102098?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 668 participants. The study started on 2019-12-31. Estimated completion is 2026-05-15.

What conditions does trial NCT04102098 study?

This clinical trial studies the following conditions: Carcinoma, Hepatocellular.

What interventions are being tested in trial NCT04102098?

The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG).

Who is sponsoring clinical trial NCT04102098?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04102098 being conducted?

This trial has 20 study locations across California, Maryland, Michigan, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Hepatocellular

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Hepatocellular

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.